Through tailored products, adaptable service and packaging choices, and unwavering support, Alpha Lifetech Inc. guarantees that researchers have access to the most fitting and efficient tools tailored to their research endeavors.
Our team of experienced scientists works closely with customers to design and execute tailored strategies for nanobody discovery, ensuring the generation of high-quality leads that align with project goals.
Antibody humanization from a broad range of parental species including mouse, rat, rabbit, llama, and avian, optimizing therapeutic compatibility.
Our Membrane Proteomics platform offers a comprehensive solution for the identification, quantification, and characterization of membrane proteins, providing valuable insights into cell interactions.
Alpha Lifetech offers native antibody libraries (scFv, Fab, VHH Formats and customized) from host animals like Goat, Camel, and Llama.
Chimeric Antigen Receptor T-cell (CAR-T) therapy has emerged as a groundbreaking pillar in modern oncology, achieving unprecedented remission rates in hematological malignancies. However, traditional CAR designs rely heavily on single-chain variable fragments (scFvs) derived from monoclonal antibodies. These conventional scFvs present significant bottlenecks: susceptibility to aggregation, complex heavy/light chain linker-induced instability, and immunogenicity, which often result in premature CAR-T cell exhaustion or severe side effects.
Our VHH Antibody Discovery Platform addresses these crucial limitations. VHH antibodies (nanobodies), derived from camelid heavy-chain-only antibodies, consist of a single monomeric variable domain. With a molecular weight of only 12-15 kDa, VHHs are exceptionally stable, highly soluble, and display low immunogenicity. By replacing scFvs with customized VHH domains, we enable the engineering of next-generation CAR-T therapies characterized by superior target affinity, diminished tonic signaling, and enhanced tumor penetration.
In the industrial biopharmaceutical landscape, VHH discovery has transitioned from an academic novelty to a primary vehicle for clinical development. The approval of the first VHH-based CAR-T therapy, Ciltacabtagene Autoleucel (Carvykti), which utilizes two BCMA-targeting VHH domains in tandem, has solidified the clinical and commercial viability of single-domain configurations. The global oncology pipeline is witnessing a massive migration toward VHH discovery platforms to construct multi-specific, modular, and off-the-shelf therapeutic candidates.
The extended CDR3 loops of VHH antibodies can penetrate deep, hard-to-reach protein clefts and active sites of cell-surface receptors that are structurally inaccessible to bulky, traditional scFvs.
Due to their small size and genetic simplicity, multiple VHH domains can be linked in tandem (bispecific or trispecific CARs) to target multiple tumor antigens simultaneously, mitigating antigen escape.
The compact genetic footprint of single-domain VHH sequences fits easily within the payload limits of lentiviral and retroviral vectors, facilitating multi-gene engineering and high viral titers.
While CAR-T therapies have excelled in treating blood cancers, solid tumors remain a formidable challenge due to the immunosuppressive tumor microenvironment (TME), physical stromal barriers, and heterogeneous antigen expression. VHH antibodies are uniquely positioned to break down these defensive mechanisms.
1. Enhanced Tissue Penetration: The physical size of VHH domains enables engineered T-cells to navigate dense extracellular matrices in solid tumors more effectively.
2. Logic-Gated CAR Architectures: Researchers utilize our VHH platform to build "AND-Gate" or "OR-Gate" logic circuits. For example, a CAR-T cell can be programmed to activate only when both target A (e.g., EGFRvIII) and target B (e.g., IL13Rα2) are engaged by their respective VHH domains, dramatically reducing off-tumor toxicities on healthy tissues.
3. Armored CAR-T Secretion: VHH sequences can be co-expressed to be secreted by CAR-T cells directly within the tumor site. These local VHHs can act as checkpoint inhibitors (e.g., anti-PD-L1 VHH) or neutralize immunosuppressive cytokines (e.g., anti-TGF-β VHH), turning the cold tumor microenvironment hot.
Alpha Lifetech Inc. was founded by a group of scientists with extensive experience in membrane protein production, nanobody discovery, monoclonal development, and other pharmaceutical pre-development services. Based on our several technology service platforms, Alpha Lifetech Inc. has launched nearly 10,000 high-quality spot membrane protein reagents, cytokines, drug target antibodies and other related reagents.
Whether you're working in the fields of immunology, cell biology, molecular biology, or any other scientific discipline, Alpha Lifetech's comprehensive range of research products will help you achieve accurate and reliable results. We pride ourselves on being able to offer a comprehensive set of high-quality products and services tailored to customer needs, which help advance the projects of scientific research institutions, academics, and enterprises in the life science industry.
Alpha Lifetech Inc. is committed to providing the highest level of customer services, competitive pricing, speedy delivery, and a comprehensive, cutting-edge product offering. Our sales and technical support staff are available to help you select the right products and service solutions. As a reliable supplier and partner, Alpha Lifetech Inc. always puts customers first. We cherish every opportunity to collaborate with worldwide customers in scientific exploration. Welcome to contact our technical support at any time.
With years of manufacturing experience, state-of-the-art facilities, and a dedicated team of Ph.D. scientists, we have supported hundreds of oncology pipelines worldwide.
Our platform utilizes phage and yeast display technology to develop different forms of antibodies: VHH single domain antibodies, Fab antibodies, and scFv antibodies, resulting in high affinity and high specificity antibodies.
The aptamer platform provided by Alpha Lifetech includes two categories: aptamer synthesis platform, which mainly involves SELEX aptamer library synthesis service and aptamer development service, and aptamer screening platform including screening services based on SELEX technology for proteins, peptides, cells, small molecules, and other target molecules, as well as aptamer optimization and identification analysis services.
Read More Platform Info
Our monoclonal antibody development services include three technologies: phage display technology, single-B cell technology, and hybridoma cell technology, which produce monoclonal antibodies for different species. These robust pathways ensure high-affinity binders suitable for downstream CAR-T validation assays.
Explore Monoclonal Services
We provide a series of technical services related to antibody engineering, stable cell line construction, yeast display, protein interaction analysis, and AAV packaging, laying a solid foundation for reliable antibody development and functional validation.
Browse Tech Services
Accelerate your CAR-T construct validation and comparative binding assays with our catalog of high-purity research-grade biosimilars.
